drugset / Trial / NCT01580618

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

NCT01580618

Phase 2/3 Terminated 20 enrolled Kaiser Permanente Genentech, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of the study is to determine the safety and efficacy of TNK infusion for the treatment of loculated pleural effusions in patients with known malignancy compared to normal saline infusion.

Timeline

Start
2008-01
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tenecteplase Protein / enzyme biologic 4 mg Other

Indications

No indication recorded.